Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)Tip Ranks·Aug 23 at 05:35 PMCOYA-5.56%
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPSMarket Beat·Aug 11 at 10:11 AMCOYA-5.56%
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseasesPUBT·Aug 11 at 07:20 AMCOYA-5.56%RDY+0.16%
Coya Therapeutics amends filing to name Mark Pavao to audit committeePUBT·Aug 7 at 04:03 PMCOYA-5.56%
Coya Therapeutics (NASDAQ:COYA) Trading Up 0.2% - Should You Buy?Market Beat·Jul 24 at 01:40 AMCOYA-5.56%JPM+0.96%
Roth MKM Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)Tip Ranks·Jul 6 at 01:05 AMCOYA-5.56%
Coya Therapeutics posts investor deck outlining Treg-directed combination therapy strategy for neurodegenerative diseasesPUBT·Jul 1 at 07:50 AMCOYA-5.56%RDY+0.16%
Coya Therapeutics shareholders approved auditor appointment for 2026 fiscal yearPUBT·Jun 25 at 04:01 PMCOYA-5.56%
Coya Therapeutics presents ALSTARS Phase 2 trial design at ENCALS 2026 meetingPUBT·Jun 18 at 07:01 AMCOYA-5.56%
Coya Therapeutics begins extension phase of ALSTARS trial for COYA 302WorldPharmaceuticals·Jun 9 at 04:25 AMCOYA-5.56%
